

(FILE 'HOME' ENTERED AT 16:47:24 ON 22 FEB 2003)

FILE 'APOLLIT, BABS, CAPLUS, CBNB, CEN, CIN, EMA, IFIPAT, JICST-EPLUS, PASCAL, PLASNEWS, PROMT, RAPRA, SCISEARCH, TEXTILETECH, USPATFULL, USPAT2, WPIDS, WTEXTILES, AGRICOLA, ALUMINIUM, ANABSTR, AQUIRE, BIOCOMMERCE, BIOTECHNO, CABA, CAOLD, CEABA-VTB, ...' ENTERED AT 16:47:45 ON 22 FEB 2003

FILE 'AGRICOLA, ALUMINIUM, ANABSTR, APOLLIT, AQUIRE, BABS, BIOCOMMERCE, BIOTECHNO, CABA, CAOLD, CAPLUS, CBNB, CEABA-VTB, CEN, CERAB, CIN, COMPENDEX, CONFSCI, COPPERLIT, CORROSION, ENCOMPLIT, ENCOMPLIT2, FEDRIP, GENBANK, INSPEC, INSPHYS, INVESTEXT, IPA, ...' ENTERED AT 16:49:04 ON 22 FEB 2003

L1	448 S	TAUROLIDINE
L2	1 S	L1 AND ANTIBIOTIC (W) RESISTAN? (W) BACTERIA
L3	88 S	L1 AND BACTERIA
L4	46 S	L3 AND ANTIBIOTIC
L5	0 S	L4 AND REISTANT STRAIN
L6	1 S	L4 AND RESISTANT STRAIN

d L1 1

L1 ANSWER 1 OF 448 ANABSTR COPYRIGHT 2003 RSC  
AN 60(7):G41 ANABSTR  
TI Quantitation of **taurolidine** decomposition in polymer solutions  
by chromotropic acid formaldehyde assay method.  
AU Sihm, Y.-S.; Guillory, J. K.; Kirsch, L. E. (Div. Pharm., Coll. Pharm.,  
Univ. Iowa, Iowa City, IA 52242, USA)  
SO J. Pharm. Biomed. Anal. (1997) 16(4), 643-650  
CODEN: JPBADA ISSN: 0731-7085  
DT Journal  
LA English

=> d l2 1 ab, kwic

L2 ANSWER 1 OF 1 USPATFULL

AB Pharmaceutical compositions are described that comprise one or more  
active ingredients selected from the group consisting of an  
anti-infective agent, anti-inflammatory agent, anti-mucolytic agent,  
antihistamine, an antiseptic, and antibiotic combinations or  
combinations of others of these classes of ingredients, and particularly  
to compositions formulated as a solution or suspension in a unit dose  
for aerosol administration to treat chronic sinusitis.

SUMM . . . all of the tablets prescribed; failure to do so may increase  
the risk for reinfection and also for development of **antibiotic**  
**-resistant bacteria**. It should be noted, however,  
that even after antibiotic treatments, between 10% and 25% of patients  
still complain of symptoms.

SUMM . . . The risk is greatest in hospitals and nursing homes, but it is  
still not high. Nonetheless, the prevalence of such **antibiotic**  
**-resistant bacteria** has increased dramatically  
worldwide, and caution should be exercised.

SUMM . . . Preferred anti-infective agents include penicillins,  
cephalosporins, macrolides, ketolides, sulfonamides, quinolones,  
aminoglycosides, beta lactam antibiotics, and linezolid. Preferred  
non-antibiotic antimicrobials include **taurolidine**. Preferred  
steroidal anti-inflammatory agents include glucocorticoids. Preferred  
nonsteroidal anti-inflammatory agents include diclofenac. Preferred mast  
cell stabilizers include cromolyn and nedcromil. . . .

DETD [0161] Examples of non-antibiotic antimicrobials include, but are not  
limited to **taurolidine**.

DETD . . . Non-antibiotic antimicrobials exhibit their activity by  
disrupting cell wall synthesis, diminishing bacterial adherence to  
mucosal walls, and neutralizing endotoxins. Specifically  
**taurolidine**, which is broken down into the amino acid taurine,  
not only has bactericidal activity but also has been shown to. . . .

DETD . . . ipratropium, atropine, and scopolamine. Preferred antiseptic  
includes iodine. Preferred antifungals include amphotericin B and azole  
antifungals. Preferred non-antibiotic antimicrobial includes  
**taurolidine**. Preferred non-steroidal anti-inflammatory agent  
includes diclofenac. These agents may be found in the American Hospital  
Formulary Service published by American. . . .

DETD [0201] As a twelfth example **taurolidine** can be formulated into  
3 ml of sterile water/normal saline for injection to provide a  
non-antibiotic antimicrobial for nebulization.

DETD [0203] 1) weigh out sufficient powder of **taurolidine** to  
provide 80 mg per dose with 5% overage for compounding losses; 2)  
dissolve the powder using a suitable diluent. . . .

DETD . . . 30-200 mg 40-150 mg 50-80 mg 60  
mg q12h

Iodide  
Rifampin Rifadin Miscellaneous 500-5000 mg 1000-4000  
mg 1500-3500 mg 2250 mg

			Q12H		
Taurolin	<b>Taurolidine</b>	Non antibiotic	5-200	mg	
20-150	mg	40-120	mg	80 mg Q12H	
		antimicrobial			
Tetrahy-	Tizine	Decongestant	0.05-0.5	mg	0.06-0.4
mg	0.1-0.3	mg.			
CLM	What is claimed is:				
	24. The composition of claim 3, wherein the non-antibiotic antimicrobial is <b>taurolidine</b> .				

L2 ANSWER 1 OF 1 USPATFULL  
 AN 2002:119301 USPATFULL  
 TI Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis  
 IN Osbakken, Robert S., Camarillo, CA, UNITED STATES  
 Hale, Mary Anne, Woodland Hills, CA, UNITED STATES  
 Leivo, Frederick T., Carpinteria, CA, UNITED STATES  
 Munk, James D., Camarillo, CA, UNITED STATES  
 PI US 2002061281 A1 20020523  
 AI US 2001-942959 A1 20010831 (9)  
 RLI Continuation-in-part of Ser. No. WO 2000-US18410, filed on 5 Jul 2000, UNKNOWN Continuation-in-part of Ser. No. US 2000-577623, filed on 25 May 2000, PENDING  
 PRAI US 1999-142618P 19990706 (60)  
 US 1999-142620P 19990706 (60)  
 US 1999-142621P 19990706 (60)  
 US 1999-142622P 19990706 (60)  
 US 1999-142624P 19990706 (60)  
 US 1999-142741P 19990706 (60)  
 US 1999-142881P 19990706 (60)  
 US 2000-193507P 20000403 (60)  
 US 2000-193508P 20000403 (60)  
 US 2000-193509P 20000403 (60)  
 US 2000-193510P 20000403 (60)  
 US 2000-194078P 20000403 (60)  
 DT Utility  
 FS APPLICATION  
 LN.CNT 1893  
 INCL INCLM: 424/043.000  
 NCL NCLM: 424/043.000  
 IC [7]  
 ICM: A61L009-04  
 ICS: A61K009-00  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 SUMM . . . all of the tablets prescribed; failure to do so may increase the risk for reinfection and also for development of **antibiotic-resistant bacteria**. It should be noted, however, that even after antibiotic treatments, between 10% and 25% of patients still complain of symptoms.  
 SUMM . . . The risk is greatest in hospitals and nursing homes, but it is still not high. Nonetheless, the prevalence of such **antibiotic-resistant bacteria** has increased dramatically worldwide, and caution should be exercised.  
 SUMM . . . Preferred anti-infective agents include penicillins, cephalosporins, macrolides, ketolides, sulfonamides, quinolones, aminoglycosides, beta lactam antibiotics, and linezolid. Preferred non-antibiotic antimicrobials include **taurolidine**. Preferred steroidal anti-inflammatory agents include glucocorticoids. Preferred nonsteroidal anti-inflammatory agents include diclofenac. Preferred mast cell stabilizers include cromolyn and nedcromil.  
 DETD [0161] Examples of non-antibiotic antimicrobials include, but are not limited to **taurolidine**.  
 DETD . . . Non-antibiotic antimicrobials exhibit their activity by disrupting cell wall synthesis, diminishing bacterial adherence to mucosal walls, and neutralizing endotoxins. Specifically **taurolidine**, which is broken down into the amino acid taurine, not only has bactericidal activity but also has been shown to.  
 DETD . . . ipratropium, atropine, and scopolamine. Preferred antiseptic includes iodine. Preferred antifungals include amphotericin B and azole antifungals. Preferred non-antibiotic antimicrobial includes **taurolidine**. Preferred non-steroidal anti-inflammatory agent includes diclofenac. These agents may be found in the American Hospital Formulary Service published by American.  
 DETD [0201] As a twelfth example **taurolidine** can be formulated into

3 ml of sterile water/normal saline for injection to provide a non-antibiotic antimicrobial for nebulization.

DETD [0203] 1) weigh out sufficient powder of **taurolidine** to provide 80 mg per dose with 5% overage for compounding losses; 2) dissolve the powder using a suitable diluent.

DETD . . . 30-200 mg 40-150 mg 50-80 mg 60 mg q12h

Iodide  
Rifampin Rifadin Miscellaneous 500-5000 mg 1000-4000 mg  
mg 1500-3500 mg 2250 mg

Taurolin **Taurolidine** Non antibiotic 5-200 mg  
20-150 mg 40-120 mg 80 mg Q12H  
antimicrobial

Tetrahy- Tizine Decongestant 0.05-0.5 mg 0.06-0.4 mg  
mg 0.1-0.3 mg.

CLM What is claimed is:  
24. The composition of claim 3, wherein the non-antibiotic antimicrobial is **taurolidine**.

AB Pharmaceutical compositions are described that comprise one or more active ingredients selected from the group consisting of an anti-infective agent, anti-inflammatory agent, anti-mucolytic agent, antihistamine, an antiseptic, and antibiotic combinations or combinations of others of these classes of ingredients, and particularly to compositions formulated as a solution or suspension in a unit dose for aerosol administration to treat chronic sinusitis.